Taro stake buyout to help operate its dermatology biz profitably amid enhanced competition: Sun Pharma
The company has issued a letter to the Taro board with a proposal containing a non-binding indication of interest to acquire all of the outstanding ordinary shares for a purchase price of USD 38 per ordinary share in cash.
